Pasithea Therapeutics (KTTA) Current Leases (2022 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Current Leases for 3 consecutive years, with $32989.0 as the latest value for Q1 2024.
- Quarterly Current Leases fell 80.0% to $32989.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $32989.0 through Mar 2024, down 80.0% year-over-year, with the annual reading at $81680.0 for FY2023, 49.07% down from the prior year.
- Current Leases hit $32989.0 in Q1 2024 for Pasithea Therapeutics, down from $81680.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $258031.0 in Q3 2022 to a low of $32989.0 in Q1 2024.
- Historically, Current Leases has averaged $142950.1 across 3 years, with a median of $162668.0 in 2022.
- Biggest five-year swings in Current Leases: surged 67.3% in 2023 and later plummeted 80.0% in 2024.
- Year by year, Current Leases stood at $160362.0 in 2022, then tumbled by 49.07% to $81680.0 in 2023, then crashed by 59.61% to $32989.0 in 2024.
- Business Quant data shows Current Leases for KTTA at $32989.0 in Q1 2024, $81680.0 in Q4 2023, and $174471.0 in Q3 2023.